Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-emicizumab antibody and coagulation test study in hemophilia A
jRCT1031230480Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of emicizumab in hemophilia A (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Activated partial thromboplastin time in anti-emicizumab antibody-positive patients, Anti-emicizumab antibodies and 6 more. Started Feb 2025; status: recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT1031230480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230480.